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ABSTRACT 
Thyroid autoimmunity and dysfunction have reported as side effects of interferon-α treatment. The CT60 
and exon 1+49 A/G polymorphisms in the Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) gene have linked 
to susceptibility to autoimmune disease. The aim of this research was to analyze the frequencies of CTLA-4 
CT60  and  +49  A/G  polymorphisms  and  evaluate  both  polymorphisms  as  indicators  of  thyroid  disorder 
susceptibility in chronic HCV Egyptian patients under interferon therapy. This study was carried out on 114 
chronic HCV patients under combined therapy of interferon-α and Ribavirin. From them, 60 chronic HCV 
patients without thyroid disorder were considered the control group. The other 54 patients were having thyroid 
disorder either hypothyroidism (N = 35) or Grave’s Disease (GD) (N = 19). For all subjects, the genotypes of 
CTLA-4  gene  CT60  and  +49  A/G  polymorphisms  were  studied  using  RFLP  technique.  For  +49  A/G 
polymorphism, the genotypes frequencies in controls were: AA (30), AG (31.7) and GG (38.3%). Whereas, in 
hypothyroidism  patients,  the  AA,  AG  and  GG  genotypes  frequencies  were  (20),  (57.1%)  and  (22.9%) 
respectively, while in grave’s disease, the AA, AG and GG genotypes frequencies were (26.3 (57.9) and 
(15.8%) respectively. The AG genotype was significantly associated with thyroid disease. As regards CT60 
polymorphism, the genotypes frequencies in controls were: CC (38.3), CT (35) and TT (26.7%). Whereas, in 
hypothyroidism patients, the CC, CT and TT genotypes frequencies were (60), (20) and (20%) respectively, 
while  in  grave’s  disease,  the  CC,  CT  and  TT  genotypes  frequencies  were  (68.4),  (15.8)  and  (15.8%) 
respectively. The CC genotype was significantly associated with thyroid disorders. CTLA-4 gene +49A/G and 
CT60 polymorphisms confer susceptibility to autoimmune thyroid disorder and confirm usefulness of CTLA-4 
genotyping in predicting thyroid disorder in chronic HCV patients under interferon therapy.  
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1. INTRODUCTION 
  Hepatitis C Virus (HCV) infection is a potentially 
life-threatening disease as 75% of affected patients with 
acute infection develop chronic disease with a high risk 
of cirrhosis and hepatocellular carcinoma (Carella et al., 
2004). Treatment of hepatitis C with pegylated interferon 
α plus Ribavirin as a Standard Of Care (SOC) for the 
management  of  this  disease,  induces  a  biochemical 
(persistent  normalization  of  alanine-aminotransferase) 
and  virological  (sustained  negativity  for  Hepatitis  C 
Virus [HCV] RNA) response and leads to eradication of 
the  virus  in  less  than  60%  of  patients  (Missiha  et  al., 
2008).  Adverse  effects  of  interferon  (IFN)  treatment Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
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include  systemic  and  organ-specific  pathological 
changes,  many  of  them  being  the  consequences  of 
immune enhancement or immune dysregulation induced 
by IFN itself (Carella et al., 2004). The main effect of 
IFN-α on the immune system is the enhancement of cell 
cytotoxicity,  which  is  important  for  antineoplastic  and 
antiviral activity (Carella et al., 2004). 
  The  widespread  effects  of  IFN  α  on  the  immune 
system  may  be  important  for  inducing  thyroid  disease 
because  peripheral  features  of  systemic  immune 
involvement have been described in patients with thyroid 
autoimmunity (Ciampolillo et al., 2003). In addition to 
the systemic effects, IFN α may have direct effects on 
the thyroid gland by modulating the aberrant expression 
of  major  histocompatibility  antigens  on  thyroid  cells 
(Carella  et  al.,  2004)  and  favoring  a  cytokine 
microenvironment,  which  may  lead  to  the  immune-
mediated damage of thyroid tissue (Wang et al., 2002a). 
Furthermore,  IFN  α  has  direct  inhibitory  effects  on 
thyroid  hormone  synthesis,  release  and  metabolism 
(Corssmit et al., 1995). However, the critical point is to 
understand how a generalized activation of the immune 
system, induced by the cytokine treatment, may result in 
an  organ-specific  involvement  of  the  thyroid  gland 
(Carella et al., 2004). A genetic predisposition to thyroid 
autoimmune  disease  is  probably  necessary  for  the 
development  of  thyroid  disease  in  patients  treated  with 
IFN α (Carella et al., 2004). 
  The Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) 
gene  on  human  chromosome  2q33  is  one  of  the 
candidate genetic markers (Weng et al., 2005). The most 
remarkable  function  of  the  CTLA-4  gene  is  down-
regulation of the humoral immune response. CTLA-4 is 
an immune regulatory molecule expressed on the surface 
of activated T lymphocytes and a key inhibitor of T cell 
activation (Kavvoura et al., 2007). 
  Genetic polymorphisms in the human genome are an 
important component of genotypic variability including 
one’s  immune  status  (Sun  et  al.,  2009).  The  CTLA-4 
gene contains several Single Nucleotide Polymorphisms 
(SNPs) that may influence gene expression, cause amino 
acid  substitution  and  alter  mRNA  splicing,  which  may 
manipulate  T-cell  activation  and,  eventually,  modulate 
host  immune  status.  Although  functional  alterations 
resulting from CTLA-4 polymorphisms seem to be subtle, 
the biological outcomes are significant. The SNPs in the 
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) gene have 
been  linked  to  susceptibility  to  autoimmune  disease    
(Sun et al., 2009). 
  Several polymorphic sites in the CTLA-4 gene (i.e, 
A/G polymorphism in exon 1 +49 (Kouki et al., 2000), 
C/T  polymorphism  in  the  promoter  -318  (Park  et  al., 
2000), microsatellite (AT)n repeat in the 3’-untranslated 
region (UTR) of exon 4 (Kouki et al., 2002) and 3 SNPs 
in  the  6.1-kb  3’  non-coding  region,  CT60,  JO31  and 
JO30)  have  been  reported  to  be  associated  with  the 
organ-specific autoimmune disorders (Ueda et al., 2003; 
Orozco et al., 2004; Torres et al., 2004) in several racial 
groups  (Furugaki  et  al.,  2004;  Weng  et  al.,  2005). 
Among  them,  CT60,  C/T  polymorphism  in  the 
promoter  -318  and  exon  1+49  A/G  SNPs  were  the 
markers  most  associated  with  autoimmune 
endocrinopathies (Vaidya and Pearce, 2004). 
  According to prior studies on the association of the 
development  of  various  autoimmune  diseases  and  the 
CTLA4  gene,  the  +49  A/G  polymorphism  in  CTLA4 
exon  1  has  been  reported  to  be  involved  in  the 
development of autoimmune diseases (Jung et al., 2009) 
including  Graves’  disease  (Yanagawa  et  al.,  1997), 
Hashimoto  thyroiditis  (Vaidya  and  Pearce,  2004),  a 
portion  of  Addison’s  disease  and  rheumatoid  arthritis 
(Vaidya et al., 2002). A significant association of Type I 
Diabetes  (T1D)  with  the  CTLA4  polymorphisms  was 
reported by Jung et al. (2009). 
  The CT60 in the 3’UTR region of CTLA4 gene is 
the  most  promising  locus  for  the  autoimmune  thyroid 
disease (Ban et al., 2005; Daroszewski et al., 2009). The 
meta-analysis  study  of  Kavvoura  et  al.  (2007),  shows 
consistent  associations  between  Graves’  disease  and 
Hashimoto  thyroiditis  with  CT60.  This  association 
crosses ethnic barriers. Although they cannot identify a 
single etiological polymorphism, their study clarifies the 
important role of the CTLA-4 locus in determining the 
risk of autoimmune thyroid diseases. 
1.1. Aim of the Study 
  Many  studies  describe  the  association  between  a 
polymorphism  of  the  CTLA-4  gene  and  autoimmune 
disease,  however,  none  of  these  previous  studies  was 
carried out in HCV patients under interferon therapy. So, 
the aim of this research is to analyze the frequencies of 
CTLA-4  CT60 and exon 1+49 A/G polymorphisms in 
chronic HCV Egyptian patients under interferon therapy 
and  to  evaluate  these  two  polymorphisms  of  CTLA-4 
gene  as  indicators  of  thyroid  disorder  susceptibility  in 
chronic HCV patients. 
2. MATERIALS AND METHODS 
2.1. Subjects 
  Fifty  four  patients  with  autoimmune  thyroid 
disorders (39 females, 15 males) were selected from a Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
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series  of  patients  receiving  combined  therapy  of 
interferon-α and Ribavirin for treatment of chronic HCV 
at  outpatient  clinic  of  tropical  medicine  at  Mansoura 
University  Hospital.  The  diagnosis  of  grave’s  disease 
was  based  on  clinical  features  of  hyperthyroidism  and 
laboratory  results  including  (a)  raised  serum  free 
thyroxine  (T4)  or  free  3,5,3’-triiodothyronine  (T3) 
levels,  suppressed  serum  thyrotropin  (TSH)  levels,  (b) 
the  presence  of  detectable  thyrotropin  receptor 
autoantibodies, antimicrosomal and/or antithyroglobulin 
antibodies  and  (c)  increased  radioactive  technetium 
uptake. The diagnosis of hypothyroidism was based on 
clinical features of hypothyroidism and laboratory results 
including low serum  free T4 or free T3 with elevated 
serum  level  of  TSH,  beside  presence  of  detectable, 
antimicrosomal  and/or  antithyroglobulin  antibodies.  In 
addition,  60  patients,  matched  for  age  and  sex,  with 
chronic HCV receiving combined therapy of interferon-α 
and  Ribavirin,  with  no  clinical  features  of  thyroid 
disorders and normal free T3, free T4 and TSH levels 
with negative thyrotropin receptor autoantibodies, anti-
microsomal  and/or  anti-thyroglobulin  antibodies  were 
also included as controls. 
  Patients having any of the following diseases were 
excluded  from  the  current  study:  diabetes  mellitus, 
chronic renal failure, coronary artery disease, end stage 
liver  disease,  malignancy,  positive  serum  Antinuclear 
Antibody (ANA). Patients and controls showing clinical 
and/or  biochemical  evidence  of  cortisol  excess  or 
deficiency,  hypogonadism,  growth  hormone  deficiency 
and pituitary adenoma were also excluded.  
  All  subjects  were  informed  of  the  purpose  of  the 
study  and  informed  consents  were  obtained  .The  study 
was  approved  by  the  ethical  committee  of  Mansoura 
University. 
2.2. Biochemical Investigation 
  All subjects were instructed to fast for at least 12 h. A 
blood sample  was  withdrawn. 5 mLs  were delivered to 
centrifuge  tubes  containing  K2EDTA  (stored  as  EDTA 
anti-coagulated  blood  sample  at  -30°C  for  DNA 
extraction). Also, plasma samples were prepared to obtain 
plasma  for  measurement  of  plasma  CTLA-4  levels. 
Another 5 mL blood sample was allowed to clot for 15 
min and centrifuged at 7000 rpm for 10 min for serum 
separation  to  determine:  liver  enzymes,  serum  albumin, 
free T3, free T4, TSH, thyrotropin receptor autoantibodies, 
antimicrosomal and/or antithyroglobulin antibodies. 
2.3. DNA Extraction 
  Genomic  DNA  was  extracted  from  EDTA-
anticoagulated  peripheral  blood  leucocytes  using  QIA 
amp DNA Blood Mini Kit supplied by Qiagen GmbH 
(Cat, No. 51104, Hiden, Germany) (Schur et al., 2001). 
The average DNA concentration (0.127 ± 0.005 µg µL
-1) 
was  determined  from  absorbance  at  260  nm  (Jenway, 
Genova  Model,  UK).  All  samples  had  a  260/280  nm 
absorbance ratio between 1.6 and 1.79. The integrity of 
the  DNA  was  checked  by  electrophoresis  on  0.8  % 
agarose gel stained with ethidium bromide. 
2.4. Genotyping  of  A/G  Polymorphism  at 
Position 49 in Exon 1 of the CTLA4 Gene 
(Jung et al., 2009) 
2.5. Polymerase Chain Reaction (PCR) 
  The primers sequences used for DNA amplification 
are  as  follow:  5’-GCTCTACTTCCTGAAGACCT-3’ 
(forward)  and  5’-AGTCTCACTCACCTTTGCAG- 
3’(reverse) (Donner et al., 1997). PCR was carried out in 
50 micro liters final reaction volume using Ready Mix 
(RED. Taq-PCR Reaction Mix) (purchased from Sigma 
Aldrich, Saint Louis, USA).The following mixture was 
prepared for each sample: 25 µL RED-Taq PCR reaction 
Mix (1´), 1µL (20 pmole) of forward primer, 1µL (20 
pmole) of reverse primer, 2µL (200ng) of genomic DNA 
and 21 µL of double distilled deionizer water. This mix 
was put in a thin wall PCR micro centrifuge tube and 
gently  centrifuged  to  collect  all  components  to  the 
bottom of the tube. Then 50µL mineral oil was added 
to prevent evaporation. Amplification was performed 
in a Thermal Cycler (Minicycler-PTC-150) using the 
following program: initial 5 min denaturation at 94°C 
followed by 30 cycles of denaturation at 94°C for 30 
sec, annealing at 55°C for 30 sec, extension at 70°C 
for 30 sec and a final extension for 7 min at 70°C. The 
resulting PCR product was 162 bp in length.  
  Amplified samples were digested with the specific 
restriction  enzyme  BbvI  (New  England  BioLabs, 
Beverly, MA, U.S.A.) at 37°C for 2h, electrophoresed on 
a  3%  agarose  gel  for  60  min,  stained  with  ethidium 
bromide,  visualized  via  Light  UV  Transilluminator 
(Model  TUV-20,  OWI  Scientific,  Inc.  800  242-5560, 
France) and photographed and evaluated. A 162 bp band 
was determined to be the A allele and the 88 bp and 74 
bp bands were determined to be the G allele (Fig. 1). 
2.6. Genotyping  of  CTLA-4  C/T-60  Single 
Nucleotide  Polymorphism  (SNP)  in  the  3’ 
Untranslated Region (Wang et al., 2007a) 
  Polymerase  Chain  Reaction  (PCR):  The  primers 
sequences  used  for  DNA  amplification  are  as  follow: 
forward primer 5’- GAGGTGAAGAACCTGTGTTAAA Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
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-3’  and  reverse  primer  5’- 
ATAATGCTTCATGAGTCAGCTT  -3’.  PCR  was 
carried out in 50 microliters final reaction volume using 
ReadyMix  (RED.  Taq-PCR  Reaction  Mix)  (purchased 
from Sigma Aldrich, Saint Louis, USA). The following 
mixture was prepared for each sample: 25 µL RED-Taq 
PCR  reaction  Mix  (1X),  1µL  (20  pmole)  of  forward 
primer, 1 µL (20 pmole) of reverse primer, 2 µL (200 
ng)  of  genomic  DNA  and  21  µL  of  double  distilled 
deionized water. This mix was put in a thin wall PCR 
microcentrifuge tube and gently centrifuged to collect 
all components to the bottom of the tube. Then 50µL 
mineral  oil  was  added  to  prevent  evaporation. 
Amplification  was  performed  in  a  Thermal  Cycler 
(Minicycler-PTC-150)  using  the  following  program: 
initial  5  min  denaturation  at  94°C  followed  by  30 
cycles of denaturation at 94°C for 30 sec, annealing at 
55°C for 30 sec, extension at 72°C for 30 sec and a 
final extension for 5 min at 72°C. The resulting PCR 
product was 178 bp in length.  
  Amplified samples  were digested with 10 units of 
the  specific  restriction  enzyme  HpyCH4IV  (New 
England-BioLabs, Beverly, MA, U.S.A.) at 37°C for 2 h, 
electrophoresed on a 3% agarose gel for 60 min, stained 
with  ethidium  bromide,  visualized  via  light  UV 
Transilluminator  (Model  TUV-20,OWI  Scientific, 
Inc.800  242-5560,  France)  and  photographed  and 
evaluated. The restriction enzyme HpyCH4 IV cuts the 
178 Base Pair (BP) PCR product only if the C allele is 
present at this site, resulting in fragments of 107 and 71 
bp. The C-60 allele yielded two bands of 107 and 71 bp 
and the T-60 allele yields a band of 178 bp (Fig. 2). 
2.7. Estimation of Plasma CTLA-4 Levels 
  Quantitative determination of plasma CTLA-4 levels 
was  performed  by  BlueGene  ELISA  Kits,  Life  Sciences 
Advanced  Technologies,  Inc.  2900  72nd  St.  N.  Saint 
Petersburg, FL 33710, USA. Cat no. E01C0628. This assay 
employs the quantitative sandwich ELISA technique which 
measures CTLA-4 in plasma. It was performed according to 
the  manufacturer’s  instructions.  The  absorbance  of  each 
sample  was read on plate ELISA reader (Tecan, Sunrise 
Absorbance reader) at 450 nm wavelength. 
2.8. Thyroid Profile Estimation 
  ELISA  kits  were  used  for  estimation  of  Free  T3 
(Diagnostic  Automation,  INC.  23961  Craftsman  Road, 
Suite D/E/F, Calabasas, CA 91302, Cat # 3148Z ), free 
T4  (Diagnostic  Automation,  INC.23961  Craftsman 
Road, Suite D/E/F, Calabasas, CA 91302, Cat # 3146Z ), 
TSH  ((Diagnostic  Automation,  INC.  23961  Craftsman 
Road, Suite D/E/F, Calabasas, CA 91302, Cat # 3122Z ). 
 
 
 
Fig. 1. Agarose gel electrophoresis analysis of the +49A/G polymorphism in CTLA-4 gene after BbvI digestion. The AA genotype is 
presented by one single band at 162 bp. (lane 4 ) and GG genotype is presented by two bands at 88 and 74 bp. (lane 2). While 
AG genotype is presented by three bands: 162, 88 and 74 bp. (lane 3). lane (1) represents the molecular marker (DNA 
molecular weight marker, purchased from promega tecnical service, catalog #G3161 Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
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Fig. 2.  Agarose gel electrophoresis analysis of the CT60 polymorphism in CTLA-4 gene after HpyCH4IV digestion.  The  TT 
genotype produced only one 178 bp band (lane 4), the CC genotype produced 2 small fragments at 107 and 71 bp 
respectively  (lane 2)  and  the CT  genotype produced  3  bands: 178, 107and 71 bp  respectively  (lane 3).  Lane (1) 
represents the molecular marke (DNA molecular weight marker, purchased from promega tecnical service, catalog 
#G3161) 
 
  Thyrotropin  receptor  autoantibodies  were  detected 
by  using  ElisaRSRTM  TRAb  3rd  Generation,  RSR 
Limited  Avenue  Park  Pentwyn  Cardiff  CF23  8HE 
United  Kingdom  (Kamijo  et  al.,  2005).  Anti-thyroid 
microsomal  and  anti-thyroglobulin  antibodies  were 
measured  by  particle  agglutination  (Serodia-AMC  and 
Serodia-ATG  diagnostic  kits,  Fujirebio  Inc.,  Tokyo, 
Japan) and were scored as positive if either was present 
at titres more than 1/l00 (Vanderpump et al., 1995). 
2.9. Lipid Profile Estimation 
  Lipid profile estimation was performed using the 
commercially  available  kits;  Total  cholesterol    
(Allian et al., 1974), triglycerides (Fossati and Prencipe, 
1982), HDL-C (Lopeo-Virella et al., 1977) and LDL-C 
(Friedewald et al., 1972).  Serum  levels  of  albumin 
(Dumas  et  al.,  1997),  Alanine  transaminase  enzyme 
(ALT)  and  Aspartate  Transaminase  enzyme  (AST) 
(Thefeld et al., 1974) were also estimated.  
2.10. Statistical Analysis 
  Data were collected, revised, verified then edited on 
personal computer and then analyzed using the Statistical 
Package  of  Social  Sciences  (SPSS)  version  16  for 
Windows  (SPSS,  Inc.,  Chicago,  IL,  USA).  Data  were 
presented using mean and Standard Deviation (SD) for 
all quantitative values and number of cases (percentage) 
for qualitative values. The distribution of tested variables 
was  examined  with  Kolmogorov-Smirnov  test  for 
normality.  The  significance  of  differences  between 
continuous  variables  was  determined  with  independent 
samples t- test for parameters with normal distribution 
and  Mann-Whitney  test  for  non  normally  distributed 
variables, as appropriate. Chi- square or Fisher exact test 
was used for comparison between qualitative variables, 
as  appropriate.  One-way  Analysis  of  Variance 
(ANOVA)  was  used  to  examine  the  mean  differences 
between  more  than  2  groups  distributed  normally  and 
Kruskal Wallis test for data not normally distributed, as 
appropriate. P values <0.05 at confidence interval 95% 
were considered significant for all statistical analyses in 
this study. 
3. RESULTS 
  This  study  was  carried  out  on  114  chronic  HCV 
patients  under  combined  therapy  of  interferon-α  and 
ribavirin. According to presence of clinical features of 
thyroid disorders, levels of free T3, free TS and TSH and 
presence  of  thyrotropin  receptor  autoantibodies, 
antimicrosomal  and/or  antithyroglobulin  antibodies,  60 
chronic  HCV  patients  under  combined  therapy  of Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
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interferon-α  and  ribavirin  without  presence  of  thyroid 
disorder were considered as a control group. The other 
54  patients  were  having  thyroid  disorder  either 
hypothyroidism (N = 35) or grave’s disease (N = 19). 
The  demographic,  clinical,  biochemical  and  hormonal 
characteristics  of  all  studied  groups  were  presented  in 
Table 1. For all subjects, the genotypes of CTLA-4 gene 
CT60 and exon 1+49 A/G polymorphisms were studied. 
  For CTLA-4  gene exon 1+49 A/G polymorphism, 
the  genotypes  frequencies  in  patients  without  thyroid 
disorder (control group)  were as follow:  AA  genotype 
was (18/60, 30%), AG genotype was (19/60, 31.7%) and 
GG genotype was (23/60, 38.3%). Whereas, in patients 
having hypothyroidism, the AA, AG and GG genotypes 
frequencies were (7/35, 20%), (20/35, 57.1%) and (8/35, 
22.9%) respectively (Table 2), while in patients having 
grave’s  disease,  the  AA,  AG  and  GG  genotypes 
frequencies  were  (3/19,  26.3%),  (11/19,  57.9%)  and 
(3/19, 15.8%) respectively (Table 3). The AG genotype 
was  significantly  associated  with  developing  either 
hypothyroidism  (odd  ratio:  2.6,  95%  CI:  1.1-6.1,  P= 
0.02) (Table 2) or grave’s disease (odd ratio: 2.97, 95% 
CI: 1.02-8.6, P = 0.039) (Table 3). The odd ratio for the 
risk of hypothyroidism associated with the G allele was 
1.4 (95% CI 0.6-3.8; P = 0.3) (Table 2), whereas, the 
odd ratio for the risk of grave’s disease associated with 
the G allele was 1.2 (95% CI 0.4-3.8; P = 0.5) (Table 3). 
This indicates non significant association of the mutant 
G  allele  with  developing  thyroid  disorder  in  chronic 
HCV  patients  under  interferon  α  therapy.
 
Table 1: Demographic, clinical, biochemical and hormonal characteristics of the studied groups 
  Controls (N = 60)  Hypothyroidism (N = 35)  GD (N = 19)       
Variables  mean ± SD  mean ± SD  mean ± SD  P1  P2 
Demographic 
Age (years)  41.8±7.6  44.3±12.6  44.8±11.90  0.200  0.200 
Gender (male/female)  36/24  7/28  8/11     
Weight (kg)  73.5±7.8  81..53±70  61±5.9000  <0.001  <0.001 
Height (m)  1.7±0.1  1.6±0.04  1.6±0.100  0.400  0.040 
BMI (kg/m
2)  27.01±3.5  30.2±2.90  23.3±2.030  <0.001  <0.001 
Clinical 
SBP (mmHg)  131.4±5.9  132.9±7.90  133.4±8.700  0.300  0.300 
DBP (mmHg)  79.3±6.1  79.7±6.10  78.7±6.200  0.800  0.700 
Biochemical and hormonal 
Plasma CTLA-4 (ng/mL)  23.1±5.70  79.2±13.04  79.6±14.100  <0.001  <0.001 
Total cholesterol (mg/dL)  187.5±26.4  202±25.6  185.8±44.700  0.010  0.800 
Triglycerides (mg/dL)  145.5±34.6  153.9±21.4  145.8±43.500  0.200  0.970 
HDL-c (mg/dL)  43.6±4.60  42.2±9.6  40.5±6.2000  0.300  0.050 
LDL-c (mg/dL)  114.8±22.6  129.02±25.41  116.2±40.400  0.006  0.900 
Free T3 (pg/mL)  3±0.5  1.6±0.4  6.6±0.8000  <0.001  <0.001 
Free T4 (ug/dL)  1.05±0.2  0.4±0.1  3.3±0.6000  <0.001  <0.001 
TSH (µIU/mL)  1.8±0.60  18.8±9.3  0.02±0.003  <0.001  <0.001 
Data are given as Mean ± SD; GD, grave’s disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CTLA-4, 
cytotoxic  T-lymphocyte-associated  antigen-4;  HDL-c,  high density  lipoprotein  cholesterol;  LDL-c,  low  density  lipoprotein  cholesterol;  T3,  tri-
iodothyronine; T4, tetra-iodothyronine; TSH, thyroid stimulating hormone; P1, hypothyroidism vs. controls; P2, hyperthyroidism vs. controls 
 
Table 2. +49 A/G and CT60 polymorphisms genotypes and alleles frequencies in hypothyroidism patients and control subjects 
Variables  Controls (n = 60)  Hypothyroid cases (n = 35)  Odd ratio(OR) (95% CI)  P 
CTLA-4 gene +49 A/G genotypes: 
G/G n (%)  23 (38.3%)  8 (22.9%)  0.48 (0.19-1.2)  0.09 
A/G n (%)  19 (31.7%)  20 (57.1%)  2.6 (1.1-6.1)  0.02 
A/A n (%)  18 (30%)  7 (20%)  0.6 (0.2-1.6)  0.20 
CTLA-4 gene +49 A/G alleles: 
G allele: n (%)  65 (54.2%)  36 (51.4%)  1.4 (0.6-3.8)  0.30 
A allele: n (%)  55 (45.8%)  34 (48.6% )  1.8 (0.7-4.5)  0.20 
CTLA-4 gene C/T60 genotypes: 
C/C  23 (38.3%)  21 (60%)  2.4 (1.02-5.7)  0.03 
C/T  21 (35%)  7 (20%)  0.5 (0.2-1.2)  0.09 
T/T  16 (26.7%)  7 (20%)  0.7 (0.3-1.9)  0.30 
CTLA-4 gene C/T60 alleles: 
C allele: n (%)  67 (55.8%)  49 (70%)  1.5 (0.5-3.9)  0.30 
T allele: n (%)  53 (44.2%)  21 (30%)  0.4 (0.2-0.97)  0.03 
OR: Odds Ratio Vs controls; CI: Confidence Interval; Significance was determined using Fisher’s exact test Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
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Table 3. +49 A/G and CT60 polymorphisms genotypes and alleles frequencies in Grave’s disease patients and control subjects 
Variables  Controls (n = 60)  Grave’s disease (n = 35)  Odd Ratio (OR) (95% CI)  P 
CTLA-4 gene +49 A/G genotypes: 
G/G n (%)  23 (38.3%)  3 (15.8%)  0.3 (0.1-1.2)  0.060 
A/G n (%)  19 (31.7%)  11 (57.9%)  2.97 (1.02-8.6)  0.039 
A/A n (%)  18 (30%)  5 (26.3%)  0.8 (0.3-2.6)  0.500 
CTLA-4 gene +49 A/G alleles: 
G allele: n (%)  65 (54.2%)  17 (44.7%)  1.2 (0.4-3.8)  0.500 
A allele: n (%)  55 (45.8%)  21 (55.3%)  3.3 (0.9-12.6)  0.060 
CTLA-4 gene C/T60 genotypes: 
C/C n (%)  23 (38.3%)  13 (68,4%)  3.5 (1.2-10.5)  0.020 
C/T n (%)  21 (35%)  3 (15.8%)  0.3 (0.1-1.3)  0.090 
T/T n (%)  16 (26.7%)  3 (15.8%)  0.5 (0.1-2)  0.300 
CTLA-4 gene C/T60 alleles: 
C allele: n (%)  67 (55.8%)  19 (76.3%)  1.9 (0.5-7.6)  0.300 
T allele: n (%)  53 (44.2%)  9 (23.7%)  0.3 (0.1-0.9)  0.020 
OR: Odds Ratio Vs controls; CI: Confidence Interval; Significance was determined using Fisher’s exact test 
 
Table 4: Biochemical and hormonal parameters in different CTLA-4 +49 A/G polymorphism genotypes and alleles in controls and autoimmune 
thyroid disease cases 
  CTLA-4 +49 A/G genotypes      CTLA-4 +49 A/G alleles 
  -------------------------------------------------------------    ------------------------------------------- 
  G/G  A/G  A/A  P value  G allele  A allele  P value 
Controls  N = 23  N = 19  N = 18    N = 65  N = 55 
CTLA-4 (ng/mL)  23.2±4.9  25.2±4.6  20.7±7.02  0.06  23.2±4.9  23±6.2  0.90 
Cholesterol (mg/dL)  180±15.8  192.3±26.8  192.1±34.8  0.20  180±15.8  192.230.5  0.08 
TG (mg/dL)  137±27.5  144.5±35.7  157.5±39.7  0.20  137±27.5  150.8±37.8  0.10 
HDL-c (mg/dL)  43.6±4  43.9±4.9  43.4±5.1  0.90  43.6±4  43.7±5  0.90 
LDL-c (mg/dL)  109±15.2  19.5±22.31  117.2±29.6  0.30  109±15.2  118.4±25.8  0.10 
Free T3 (pg/mL)  3.01±0.5  3.01±0.5  2.9±0.6  0.80  3.02±0.5  3±0.5  0.70 
Free T4 (ng/dL)  0.9±0.2  1.1±0.3  1.1±0.2  0.40  0.99±0.2  1.1±0.2  0.20 
TSH (µIU/mL)  1.6±0.5  2±0.8  1.8±0.6  0.30  1.6±0.5  1.9±0.7  0.10 
Hypothyroidism  N = 8  N = 20  N = 7    N = 36  N = 34 
 CTLA-4 (ng/mL)  73.6±10.9  78.7±13.8  87.1±10.1  0.10  76.3±13.1  80.2±13.1  0.30 
Cholesterol (mg/dL)  197.1±25.1  205.5±30  197.6±4.7  0.70  195.8±23.9  204.2±26.3  0.90 
TG (mg/dL)  142.8±25.1  157.5±21.7  156.4±12.5  0.20  148±28.3  155.9±18.7  0.30 
HDL-c (mg/dL)  38.3±4.8  43.8±11.6  42.3±6.5  0.60  38.8±4.7  43.4±10.6  0.40 
LDL-c (mg/dL)  130.3±23.3  130.3±30.3  124±9.3  0.70  127.4±23.4  129.6±26.5  0.90 
Free T3 (pg/mL)  1.7±0.3  1.7±0.4  1.5±0.6  0.90  1.6±0.4  1.6±0.4  0.90 
Free T4 (ng/dL)  0.4±0.1  0.4±0.1  0.4±0.1  0.90  0.4±0.1  0.4±0.1  0.80 
TSH (µIU/mL)  23.5±10  17.8±10  16.3±4.9  0.09  22.3±10  17.6±9  0.08 
Grave’s disease  N=3  N=11  N=5    N=17  N=21 
 CTLA-4 (ng/mL)  71±13.2  77.6±14.8  89±9.2  0.10  71±13.2  81.2±14.1  0.30 
Cholesterol (mg/dL)  176.7±41.6  197.3±47.9  166±38.5  0.40  176.7±41.6  187.5±46.3  0.80 
TG (mg/dL)  130±43.6  162.7±44.1  118±27.7  0.09  130±43.6  148.8±44.3  0.40 
HDL-c (mg/dL)  38.3±7.6  39.5±6.5  43.8±4.1  0.40  38.3±7.6  40.9±6.1  0.60 
LDL-c (mg/dL)  112.3±41.8  125.2±43.5  98.633.3  0.30  112.3±41.8  116.9±41.5  0.90 
Free T3 (pg/mL)  6±0.2  6.6±0.9  6.9±0.8  0.30  6±0.2  6.7±0.9  0.20 
Free T4 (ng/dL)  3.8±0.9  3.3±0.5  3.1±0.7  0.50  3.8±0.9  3.2±0.6  0.30 
TSH (µIU/mL)  0.01±0.01  0.03±0.03  0.008±0.007  0.60  0.01±0.01  0.02±0.02  0.80 
Data  are  given  as  Mean  ±  SD.;  CTLA-4,  cytotoxic  T-lymphocyte-associated  antigen-4;  TG,  triglycerides;  HDL-c,  High  Density  Lipoprotein 
cholesterol; LDL-c, Low Density Lipoprotein cholesterol; T3,Tri-Iodothyronine; T4, Tetra-Iodothyronine; TSH, Thyroid Stimulating Hormone 
 
  As regards CTLA-4 gene CT60 polymorphism, the 
genotypes  frequencies  in  patients  without  thyroid 
disorder  (control  group)  were  as  follow:  CC  genotype 
was (23/60, 38.3%), CT genotype was (21/60, 35%) and 
TT genotype was (16/60, 26.7%). Whereas, in patients 
having hypothyroidism, the CC, CT and TT genotypes 
frequencies were (21/35, 60%), (7/35, 20%) and (7/35, 
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grave’s  disease,  the  CC,  CT  and  TT  genotypes 
frequencies  were  (13/19,  68.4%),  (3/19,  15.8%)  and 
(3/19, 15.8%) respectively (Table 3). The CC genotype 
was  significantly  associated  with  developing  either 
hypothyroidism (odd ratio: 2.4, 95% CI: 1.02-5.7, p = 
0.03) (Table 2) or grave’s disease (odd ratio: 3.5, 95% 
CI: 1.2-10.5, p = 0.02) (Table 3). The odd ratio for the 
risk of hypothyroidism associated with the T allele was 
0.4 (95% CI 0.2-0.97; p = 0.03) (Table 2), whereas, the 
odd ratio for the risk of grave’s disease associated with 
the T allele was 0.3 (95% CI 0.1-0.9; p = 0.02) (Table 3). 
This indicates significant association of the mutant T allele 
with developing thyroid disorder in chronic HCV patients 
under  interferon  α  therapy.  However,  the  different 
genotypes and alleles distributions between control group 
and  either  hypothyroidism  or  grave’s  disease  were 
indicative that TT genotype and the T allele are consider 
protective against developing thyroid disorder in chronic 
HCV patients under interferon α therapy.  
  The plasma CTLA-4 level was significantly increase 
(than controls) with presence of either hypothyroidism (P 
=  0.001)  or  grave’s  disease  (p  =  0.001)  (Table  1). 
However, all the hormonal and biochemical parameters, 
including plasma CTLA-4 level, were non significantly 
different  in  different  CTLA-4  gene  +49  A/G 
polymorphism genotypes or alleles groups either in the 
control,  hypothyroidism,  or  grave’s  disease  groups 
(Table 4). In addition, in different CTLA-4 gene CT60 
polymorphism  genotypes  and  alleles  groups  in  the 
control,  hypothyroidism  and  grave’s  disease  groups 
(Table  5),  all  the  hormonal  and  biochemical 
parameters, including plasma CTLA-4 level, were non 
significantly different except that the triglycerides and 
free T3 were significantly different in different CT60 
genotypes (p = 0.03) and different alleles groups (p = 
0.02)  in  hypothyroidism  group.
 
Table 5: Biochemical and hormonal parameters in different CTLA-4 C/T60 polymorphism genotypes and alleles in controls and autoimmune thyroid 
disease cases 
  CTLA-4 genotypes        CTLA-4 alleles 
  ---------------------------------------------------------    ---------------------------------- 
  C/C  C/T  T/T  P value  C allele  T allele  P value 
Controls  N = 23  N = 21  N = 16    N = 67  N = 53 
Plasma CTLA-4 (ng/mL)  22.5±6.1  23.6±5.3  23.2±6.01  0.80  22.5±6.1  23.4±5.5  0.50 
Cholesterol (mg/dl)  185.7±28.6  193.3±28.6  182.4±19.4  0.40  185.8±28.6  188.6±25.3  0.70 
TG (mg/dl)  149.1±34  149.5±34.7  135±35.4  0.50  149.1±34  143.2±35.3  0.50 
HDL-c (mg/dl)  44.5±4.1  43.5±5.6  42.6±3.6  0.40  44.5±4.1  43.1±4.8  0.30 
LDL-c (mg/dl)  111.4±24.2  120±25.2  112.8±15.9  0.40  111.4±24.2  116.9±21.7  0.40 
Free T3 (pg/mL)  2.9±0.5  3.1±0.5  3±0.5  0.70  2.9±0.5  3.03±0.5  0.40 
Free T4 (ng/dl)  1.1±0.2  1.04±0.2  1.01±0.2  0.70  1.1±0.2  1.03±0.2  0.50 
TSH (µIU/mL)  1.7±0.6  1.8±0.6  1.9±0.7  0.80  1.7±0.6  1.8±0.6  0.60 
Hypothyroidism  N=21  N=7  N=7    N=49  N=21 
Plasma CTLA-4 (ng/mL)  78.7±9.9  85±15.4  75±18.4  0.30  78.7±9.9  80±17.1  0.30 
Cholesterol (mg/dl)  201.1±20.8  188.4±16.4  218.1±38.4  0.20  201.1±20.8  203.3±32.3  0.20 
TG (mg/dl)  147.3±20  171.9±19  155.7±19.2  0.03  147.3±20  163.8±20.2  0.02 
HDL-c (mg/dl)  41.2±8.9  37.6±6.1  49.9±11.03  0.08  41.2±8.9  43.7±10.7  0.40 
LDL-c (mg/dl)  130.5±25.4  116.5±16.5  17.1±31.3  0.20  130.5±25.4  126.8±26.3  0.30 
Free T3 (pg/mL)  1.7.3±0  1.3±0.5  1.5±0.5  0.03  1.7±0.3  1.4±0.4  0.02 
Free T4 (ng/dl)  0.4±0.1  0.4±0.1  0.4±0.1  0.50  0.4±0.1  0.4±0.1  0.60 
TSH (µIU/mL)  18.9±10.6  15.3±3.4  22±9.5  0.50  18.9±10.6  18.6±7.7  0.70 
Grave’s disease  N = 13  N = 3  N = 3    N = 29  N = 9 
 CTLA-4 (ng/mL)  80.8±12.1  83.7±12.4  70±24.2  0.70  80.8±12.1  76.8±18.8  0.70 
Cholesterol (mg/dl)  195.4±40.1  185±67.6  145±26  0.10  195.4±40.1  165±50.8  0.07 
TG (mg/dl)  153.8±42.3  143.3±61.1  113.3±23.1  0.30  153.8±42.3  128.3±44.5  0.20 
HDL-c (mg/dl)  39.5±6.9  39.3±2.3  46±1.7  0.20  39.5±6.9  42.7±4.1  0.40 
LDL-c (mg/dl)  125.2±36.7  117±57.5  76.3±19.6  0.10  125.2±36.7  96.7±44.4  0.07 
Free T3 (pg/mL)  6.7±0.9  6.4±0.8  6.6±0.8  0.50  6.7±0.9  6.3±0.5  0.30 
Free T4 (ng/dl)  3.3±0.6  3.2±0.9  3.3±0.6  0.90  3.3±0.5  3.3±0.9  0.90 
TSH (µIU/mL)  0.02±0.03  0.02±0.01  0.02±0.02  0.05  0.02±0.03  0.01±0.01  0.20 
Data  are  given  as  Mean  ±  SD.;  CTLA-4,  cytotoxic  T-lymphocyte-associated  antigen-4;  TG,  triglycerides;  HDL-c,  high  density  lipoprotein 
cholesterol; LDL-c, low density lipoprotein cholesterol; T3,tri-iodothyronine; T4, tetra-iodothyronine; TSH, thyroid stimulating hormone Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
 
187  Science Publications
 
AJBB 
4. DISCUSSION 
  Hepatitis C virus is a highly immunogenic pathogen 
often  inducing  autoimmune  activation  changes,  it  can 
modulate T cell and B cell antibody responses, affecting 
many  endocrine  organs,  most  commonly  the  thyroid 
(Tran  and  Reeves,  2009).  This  is  further  exacerbated 
with  the  use  of  interferon-α  therapy  (Tran,  2010). 
Treatment  of  chronic  HCV  (CHC)  infection  with 
Interferon  α  (IFN)  plus  Ribavirin  has  been  associated 
with  thyroid  dysfunction,  in  which  activation  of  the 
immune  system  is  important  for  the  development  of 
thyroid disease (Carella et al., 2004). 
  Human  chromosome  region  2q33  contains  three 
genes  known  to  be  involved  in  immune  regulation 
(Coyle  et  al.,  2000).  Two  of  these  genes  appear  to 
positively regulate immune responses. These are the CD28 
receptor gene and the Inducible Co-Stimulator (ICOS) gene. 
A third gene appears to be a negative regulator of T cell 
activation; namely, CTLA-4 (Tivol et al., 1995). It is thus 
not surprising that genetic variation within this region is 
implicated  in  susceptibility  to  autoimmune  disease 
(Berry  et  al.,  2008).  The  association  of  autoimmune 
diseases  with  the  CTLA-4  locus  could  represent  the 
effects  of  any  of  these  three  genes  alone  or  in 
combination due to linkage  disequilibrium. Ban et al., 
(2004) and Ueda et al. (2003) were able to show that 
CTLA-4 and not CD28 or ICOS was the susceptibility 
gene at this locus. 
  In  addition,  CTLA4  has  been  considered  to  be  a 
permissive  candidate  gene  involved  in  the  etiology  of 
autoimmune  diseases;  this  is  because  CTLA-4  plays  a 
role in the regulation of the activation of T cells and as 
well as T cell and B cell interactions (Jung et al., 2009). 
  Extensive  population  genetics  studies  have 
suggested  associations  between  SNPs  in  and  around 
CTLA-4  locus  on  chromosome  2  in  man  and  the 
presence of autoimmune disease (Gough et al., 2005). 
The first of these reports was made by Yanagawa et al. 
(1995),  who  found  a  significant  association  between 
variation in the (AT) dinucleotide repeat within the 3’-
untranslated region of the CTLA-4 gene and the presence 
of Grave’s Disease (GD). Subsequent to these findings, 
many  others  have  reported  associations  between  SNPs 
within and around the CLTA-4 region and rheumatoid 
arthritis  (Lei  et  al.,  2005),  celiac  disease  (Hunt  et  al., 
2005),  type  I  diabetes  (Jung  et  al.,  2009),  myasthenia 
gravis (Wang et al., 2008) and autoimmune pancreatitis 
(Chang et al., 2007). Furthermore, the CTLA-4 gene has 
also been implicated in other autoimmune disorders like 
Hoshimoto’s  Thyroiditis  (HT)  (Kotsa  et  al.,  1997), 
Addison’s  disease  (Vaidya  et  al.,  2002)  and  Multiple 
sclerosis (Kouki et al., 2000). 
  Furthermore, the association between CTLA-4 gene 
and  autoimmune  thyroid  diseases  has  been  consistent 
across  populations  of  different  ethnic  backgrounds, 
such  as  Caucasians  (Heward  et  al.,  1999),  Japanese 
(Akamizu et al., 2000) and Koreans (Park et al., 2000). 
  Although,  many  studies  describe  the  association 
between  a  polymorphism  of  the  CTLA-4  gene  and 
autoimmune disease, none of these previous studies was 
carried out in HCV patients under interferon therapy. So, 
the aim of this research was to analyze the frequencies of 
CTLA-4 CT60 and exon 1+49 A/G polymorphisms and 
evaluate  both  polymorphisms  as  indicators  of  thyroid 
disorder susceptibility in chronic HCV Egyptian patients 
under interferon therapy. 
  This  study  was  carried  out  on  114  chronic  HCV 
patients  under  combined  therapy  of  interferon-α  and 
Ribavirin. From them, 60 chronic HCV patients under 
combined therapy of interferon-α and Ribavirin without 
presence of thyroid disorder were considered as a control 
group.  The  other  54  patients  were  having  thyroid 
disorder  either  hypothyroidism  (N  =  35)  or  Grave’s 
Disease (GD) (N = 19). For all subjects, the genotypes of 
CTLA-4 gene CT60 and exon 1+49 A/G polymorphisms 
were studied using RFLP technique. 
  In this study, the +49 A/G genotypes frequencies in 
Egyptian  patients  without  thyroid  disorder  (control 
group)  were  as  follow:  AA  genotype  was  (30AG 
genotype  was  (31.7)  and  GG  genotype  was  (38.3%). 
This can be added to the results of other studies in which 
the  distribution  of  genotypes  (GG,  AG  and  AA)  for 
CTLA-4  gene  polymorphism  varies  among  different 
populations  including  Caucasians  (Yanagawa  et  al., 
1995),  Japanese  (Yanagawa  et  al.,  1997),  Koreans   
(Park  et  al.,  2000),  Hong  Kong  Chinese  children   
(Chong et al., 2008) and Taiwanese (Weng et al., 2005).  
  According  to  the  SNP  database  of  the  National 
Center  for  Biotechnology  Information 
(www.ncbi.nlm.nih.gov/SNP),  the  allele  frequencies  of 
exon1 +49 A/G are very different across ethnicities. The 
risk  G  allele  of  exon1  +49  A/G  is  more  frequent  in 
Asians  (65than  Caucasians  (20)  or  Africans  (29%) 
(Wang et al., 2007b). 
  The  present  study  shows  that  the  ‘‘G’’  allele 
frequency in Egyptians was 54% in controls and 44% in 
GD patients. Previous studies reported that the highest 
‘‘G’’ allele frequency (76%) was noted in Chinese GD 
population (Wang et al., 2004). The lowest ‘‘G’’ allele Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
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frequency  (48%)  was  noted  in  Caucasian  GD 
population and among healthy individuals in Iranian 
(37%)  (Kalantari  et  al.,  2003)  and  Caucasian 
population (38%) (Bednarczuk et al., 2003). The study 
of Veeramuthumari et al. (2011), shows that the ‘‘G’’ 
allele  frequency  is  63%  among  South  Indian 
population,  which  is  comparable  to  that  of  the 
Taiwanese ‘‘G’’ allele frequency (67%) (Weng et al., 
2005) and Koreans (68%) (Park et al., 2000). 
  As regards the results of current research in thyroid 
disease  patients,  for  CTLA-4  gene  exon  1+49  A/G 
polymorphism,  the  AG  genotype  was  significantly 
increased  and  was  significantly  associated  with 
developing  thyroid  disorder  either  hypothyroidism  or 
grave’s disease. However, the mutant G allele was non 
significantly  associated  with  thyroid  disorder.  The 
genotype AA was decreased in patients having thyroid 
disorders  and  the  odd  ratio  for  the  risk  of 
hypothyroidism  associated  with  the  G  allele  was  1.4 
(95% CI 0.6-3.8; p = 0.3), whereas, the odd ratio for the 
risk of grave’s disease associated with the G allele was 
1.2 (95% CI 0.4-3.8; p = 0.5). 
  The decrease in the AA genotype and increase in the 
AG genotype is in accordance with previous studies on 
CTLA-4  gene  function.  It  encodes  a  co-stimulatory 
molecule,  which is expressed on activated T cells and 
may mediate T cell apoptosis (Kouki et al., 2000).  In 
vitro  studies  showed  that  the  A/G  Single  Nucleotide 
Polymorphism (SNP) at position 49 (exon 1, codon 17) 
of  the  CTLA4  gene  leads  to  a  Thr/Ala  amino  acid 
substitution in the leading peptide and is associated with 
impaired function of this receptor (Kouki et al., 2000). 
Thus  CTLA-4  is  a  strong  candidate  gene  for  T  cell-
mediated autoimmune diseases (Bednarczuk et al., 2003). 
  As reported previously, the distribution of CTLA-4 
alleles  differed  significantly  between  control  subjects 
and Grave’s Disease (GD) patients. In both Caucasian 
and  Japanese  patients  with  GD  (Bednarczuk  et  al., 
2003),  the  frequency  of  G  allele  and  G/G  genotype 
were  significantly  higher  compared  with  healthy 
subjects.  However,  the  relative  risks  for  developing 
Graves’ disease in Caucasians and Japanese conferred 
by  G  allele  (1.5  and  1.6  respectively)  or  by  G/G 
genotype  (1.7  and  2.1  respectively)  were  different  to 
the values found in our study (1.2 by G allele and 0.3 
by GG genotype). 
  In  accordance  with  our  results,  studies  conducted 
among  different  populations  showed  an  association  of 
CTLA-4  gene  49  A/G  polymorphism  with  Graves’ 
disease  including  Caucasians  (Yanagawa  et  al.,  1995), 
Japanese (Yanagawa et al., 1997), Koreans (Park et al., 
2000),  Chinese  children  (Chong  et  al.,  2008)  and 
Taiwanese  (Weng  et  al.,  2005)  and  in  South  Indian 
population (Veeramuthumari et al., 2011). However, the 
study  of  Frydecka  et  al.  (2004),  showed  that  the 
distribution of CTLA-4 exon 1 A (49)G genotype, allele 
and phenotypic frequencies did not differ between patients 
with GD and healthy subjects in Polish population.  
  Furthermore,  our  study  indicates  that  the  A/G 
genotype in the exon 1 +49 SNP is predominant in the 
Egyptian  thyroid  patients  and  that  it  is  higher  in  GD 
patients,  compared  to  control  subjects  (p  =  0.039). 
Compared to studies of other racial groups, our results 
are similar. A number of findings, including our study of 
association between exon 1 +49 SNP and GD, supported 
the theory that the exon 1 +49 SNP of  CTLA-4 gene 
leads to genetic susceptibility to GD as a general rule 
(Kouki  et  al.,  2002;  Kinjo  et  al.,  2002;  Weng  et  al., 
2005; Wang et al., 2007b). 
  Nithiyananthan et al. (2002), reported, in the United 
Kingdom patients, a significant excess of the G allele in 
patients  with  autoimmune  hypothyroidism  compared 
with  controls  (43%  Vs  32%  respectively;  odds  ratio 
1.57) and that the AG genotype was found to be more 
frequent  in  patients  with  autoimmune  hypothyroidism 
than  controls  (50%  Vs  46%  respectively;  p  =  0.003). 
This is in accordance with our results (the AG genotype 
was significantly increase in hypothyroidism patients than 
control; 57.1 Vs 31.7 respectively, P = 0.02; odds ratio 
2.6). In addition, Kouki et al. (2000) and Donner et al. 
(1997)  reported  a  higher  frequency  of  G/G  and  A/G 
genotypes and lower frequency of A/A alleles in patients 
with  Hashimoto  thyroiditis.  These  previous  results 
together with our results, suggest that the CTLA-4 gene 
region on chromosome 2q33 is a susceptibility locus for 
autoimmune hypothyroidism.  
  The fact that some control individuals bearing the 
G/G  genotype  do  not  develop  autoimmune  diseases 
whereas  some  patients  with  the  A/A  genotype  suffer 
from autoimmunity underlines the multifactorial etiology 
of autoimmune diseases(Kouki et al., 2000).  
  Although  the  function  of  CTLA-4  protein  is 
probably  unaffected  by  the  exon  1  +49  SNP,  it  may 
influence the level or pattern of protein expression. The 
G  allele  is  associated  with  reduced  control  of  T  cell 
proliferation and thus contributes to the pathogenesis of 
GD,  hypothyroidism  and  presumably  of  other 
autoimmune diseases (Kouki et al., 2000). 
  In  the  present  study,  we  observed  significantly 
increased serum CTLA-4 levels in GD and hypothyroidism 
patients  compared  with  controls.  Our  results  are  in 
agreement  with  those  of  Oaks  and  Hallet  (2000);     
Saverino et al. (2007) and Daroszewski et al. (2009).  Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
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  Expression of CTLA-4 appears to be selectively 
induced  in  certain  pathological  conditions  in  vivo. 
Ligers  et  al.  (2001),  have  shown  that  cell-surface 
expression  of  CTLA-4  protein  is  influenced  by 
common  polymorphisms  in  the  promoter  and  first-
exon sequences. Furthermore, the effect seems to be 
related  to  the  position  49  of  the  leader  sequence 
(Ligers et al., 2001).  
  The influence of the polymorphisms within CTLA-
4 gene on the GD has been widely studied. The CT60 
in  the  3’UTR  region  of  this  gene  was  the  most 
promising  locus  for  the  autoimmune  thyroid  disease 
(Daroszewski  et  al.,  2009;  Petrone  et  al.,  2005;        
Weng et al., 2005). 
  As  regards  CTLA-4  gene  CT60  polymorphism  in 
current  study,  the  genotypes  frequencies  in  patients 
without thyroid disorder (control group) were as follow: 
CC genotype was (38.3%), CT genotype was (35%) and 
TT genotype was (26.7%). Whereas, in patients having 
hypothyroidism,  the  CC,  CT  and  TT  genotypes 
frequencies were (60%), (20%) and (20%) respectively, 
while in patients having grave’s disease, the CC, CT and 
TT  genotypes  frequencies  were  (68.4%),  (15.8%)  and 
(15.8%) respectively. The CC genotype was significantly 
associated  with developing either  hypothyroidism (odd 
ratio: 2.4, 95% CI: 1.02 – 5.7, p = 0.03) (Table 2) or 
grave’s disease (odd ratio: 3.5, 95% CI: 1.2-10.5, P = 
0.02). There was a significant decrease of the mutant T 
allele with developing thyroid disorder in chronic HCV 
patients  under  interferon  α  therapy.  The  different 
genotypes  and  alleles  distributions  between  control 
group and either hypothyroidism or grave’s disease were 
indicative that TT genotype and the T allele are consider 
protective against developing thyroid disorder in chronic 
HCV patients under interferon α therapy.  
  The significant increase in CC genotype in thyroid 
disease  patients  supports  that  The  CT60  SNP  is 
potentially important because it may be associated with 
an alteration in the ratio of splice forms of the CTLA4 
gene and this ratio may affect disease susceptibility, as 
reported by Ueda et al. (2003). 
  Weng  et  al.  (2005),  demonstrated  that  the  G/G 
genotype  of  the  CT60  SNP  is  most  prevalent  in  the 
Taiwanese  population  and  there  are  more  Grave’s 
Disease (GD) patients having G allele (G/G genotype) 
and  fewer  patients  having  A  allele  (A/A  or  A/G 
genotype),  compared  to  the  control  subjects.  Other 
studies in different populations support the results of the 
present study (Daroszewski et al., 2009; Petrone et al., 
2005; Ban et al., 2005). 
  In the present study, the C allele was increased in 
both  GD  (76.3%)  and  hypothyroidism  (70%)  patients 
than controls (55.8%). The odd ratio for the C allele was 
1.9  for  GD  and  1.5  for  hypothyroidism.  This  is  in 
agreement  with  the  study  of  Ban  et  al.  (2005),  that 
reported  CT60  to  be  most  strongly  associated  with 
Autoimmune Thyroid Disease (AITD). In that study, the 
G  allele  of  the  CT60  was  associated  with  GD  than 
control (84.0 vs 72.6%, P = 0.0008) and AITD (80.1 vs. 
72.6%, P = 0.009) in the Japanese. Furthermore, the G 
allele of the CT60 was associated with the increased risk 
for GD [P = 0.004, Odds Ratio (OR) = 2.0] and AITD (P 
= 0.03, OR = 1.6).  
  In addition, according  to the SNP database of the 
National  Center  for  Biotechnology  Information 
(www.ncbi.nlm.nih.gov/SNP), the risk G allele of CT60 
is more common in Asians (70%) and Africans (80%) 
than Caucasians (50%) (Wang et al., 2007b). 
  In the present study, the plasma CTLA-4 level was 
significantly increase (than controls) with presence of 
either hypothyroidism (p = 0.001) or grave’s disease 
(p = 0.001). 
  The  CT60-A/G  Single  Nucleotide  Polymorphism 
(SNP) is believed to control the processing and production 
of  soluble  CTLA-4  (sCTLA-4)  (Purohit  et  al.,  2005). 
Also,  the  susceptible  CT60-G  allele  was  reported  to 
produce a lower amount of soluble CTLA-4 mRNA in 
the  peripheral  blood  lymphocytes  than  the  disease 
resistant  CT60-A  allele  (Purohit  et  al.,  2005).  These 
results  suggested  that  sCTLA-4  may  confer  protective 
effect against autoimmune diseases. If this effect is true, 
a  researcher  would  predict  a  lower  sCTLA-4  in  the 
serum  in  autoimmune  diseases  patients  compared  to 
controls.  However,  this  prediction  is  in  direct  conflict 
with  our  results  and  with  the  observations  of  other 
studies  in  most  autoimmune  diseases  including 
autoimmune  thyroid  disease  (Oaks  and  Hallett,  2000), 
systemic  lupus  erythematosus  (Liu  et  al.,  2003)  and 
myasthenia  gravis  (Wang  et  al.,  2002b),  in  which  the 
serum  sCTLA-4  levels  are  increased  in  patients 
compared to controls.  
  So,  elevated  sCTLA-4  that  has  been  reported  in 
these autoimmune diseases suggests that sCTLA-4 may 
contribute to the development of autoimmune diseases, 
probably  through  down-regulation  of  T  cell  activation 
(Purohit et al., 2005). 
  In the present study, in the co-occurrence of the 2 
polymorphisms (CT60 SNP and exon 1 +49), there are 
significantly  more  Grave’s  Disease  (GD)  and 
hypothyroidism patients that carry G alleles in the CT60 
SNP and exon 1 +49 SNP, compared to control subjects. Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
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When the CT60 SNP genotype is G/G, the frequency of 
A/G  genotype  in  the  exon  1  +49  SNP  is  higher.  Our 
results  confirmed  that  the  presence  of  at  least  one  G 
allele (GG or AG) at either locus confers susceptibility to 
thyroid  disorder.  This  is  in  agreement  with  results  of 
other studies (Weng et al., 2005; Petrone et al., 2005; 
Chong et al., 2008). These results highlight the role of 
the CTLA-4 locus, in the susceptibility to GD.  
  The Kavvoura et al. (2007), meta-analysis study for 
both  CT60  SNP  and  exon  1  +49  SNPs,  examined  the 
association of CTLA-4 polymorphisms with autoimmune 
thyroid disease (GD and HT) and included group-level 
data from more than 13,000 subjects and individual-level 
data from more than 5,000 subjects. The group-level data 
clearly  showed  highly  significant  associations  of  both 
GD and HT with each polymorphism separately (CT60 
SNP and exon 1 +49), with P values in the range of 10
−3 
to 10
−16 in the main analyses.  
  Exon1  +49  A/G  (21)  and  CT60  SNPs  have  been 
shown  to  have  biological  relevance.  Both  of  the  two 
SNPs have A and G alleles and G is the risk allele for 
either  of  the  two  loci.  Although  Ueda  et  al.  (2003), 
reported  that  CT60  is  the  major  causal  variant  in 
determining  mRNA  expression,  they  did  not  find  the 
susceptible  haplotype  GG  carried  a  higher  risk  than 
single allele G of exon1 +49 A/G polymorphism. This 
may  be  due  to  complex  regulation  of  gene  expression 
(for example other functional locus not considered or the 
discrepancy between gene expression and protein levels) 
(Wang et al., 2007b). 
  According  to  the  SNP  database  of  the  National 
Center  for  Biotechnology  Information 
(www.ncbi.nlm.nih.gov/SNP),  the  allele  frequencies  of 
exon1 +49 A/G are very different across ethnicities. The 
risk  G  allele  of  exon1  +49  A/G  is  more  frequent  in 
Asians (65%) than Caucasians (20%) or Africans (29%). 
Similarly, the risk G allele of CT60 is more common in 
Asians  (70%)  and  Africans  (80%)  than  Caucasians 
(50%).  Therefore,  the  two  polymorphisms  provide 
different  statistical  powers  for  different  study 
populations (Wang et al., 2007b). 
  The  results  of  the  present  study  revealed  that 
plasma CTLA-4 level was not significantly different in 
different  CTLA-4  gene  +49  A/G  or  CT60 
polymorphisms genotypes or alleles groups either in the 
control,  hypothyroidism,  or  grave’s  disease  groups. 
Thus, our data do not support a relationship between 
these tested SNPs and circulating levels of CTLA-4 in 
the presence or absence of autoimmune disease. These 
results are in agreement with the study of Berry et al. 
(2008),  who  found  no  statistically  significant 
differences  in  observed  versus  expected  genotypic 
frequencies  for  these  SNPs  when  comparing  positive 
versus negative blood levels of sCTLA-4.  
  Furthermore,  our  data  confirm  and  extend  the 
findings of  Purohit et al. (2005), who reported a lack of 
association  between  CT60  genotype  and  sCTLA-4 
levels. On the other hand, our findings appear to be at 
odds with the speculation that the CTLA-4 CT60-A/G 
SNP may determine the alternate splicing and production 
of  the  sCTLA-4  mRNA.  In  the  Ueda  et  al.  (2003), 
model,  the  CT60-G  susceptibility  allele  appears  to 
produce lower relative amounts of the sCTLA-4 mRNA; 
thus,  one  would  expect  that  subjects  at  risk  for 
autoimmune disease to have reduced levels of sCTLA-4 
protein. It seems paradoxical given that lower levels of 
CTLA-4 message are present in susceptible individuals 
whereas higher levels of sCTLA-4 protein are observed 
in  plasma  of  individuals  with  autoimmune  disease 
(Berry  et  al.,  2008).  Possible  explanations  for  the 
appearance  of  this  discrepancy  may  include  the 
possibility that there is no direct relationship between 
message  levels  at  the  cellular  level  and  circulating 
protein  in  plasma.  For  example,  elevated  circulating 
CTLA-4 levels may simply be due to increased half-life 
and/or decreased turnover of protein despite increased 
levels of synthesis. Also, it is possible that lower levels 
of CTLA-4 message reflect a feedback regulatory loop 
in which mRNA levels are reduced in the face of higher 
levels of CTLA-4 protein (Berry et al., 2008). 
  Although  the  size  of  our  samples  (patients  and 
controls)  was  not  large,  the  difference  in  CTLA-4 
genotypes  frequencies  between  control  subjects  and 
patients was significant. Probably incorporation of both 
SNPs (CT60 SNP and exon 1 +49 SNP) markers further 
increases predictive accuracy and enhances the role of 
the CTLA-4 in thyroid disorders.  
5. CONCLUSION 
  Our  results  showed  that  CTLA-4  gene  +49A/G 
and CT60 polymorphisms conferred susceptibility to 
autoimmune  thyroid  disorders  and  confirm  the 
usefulness  of  the  CTLA-4  genotyping  in  predicting 
thyroid  disorder  in  chronic  HCV  Egyptian  patients 
under interferon therapy.  
  Although  researchers  still  cannot  identify  a  single 
etiological  polymorphism,  our  study  confirms  the 
important role of the CTLA-4 locus in determining the 
risk of autoimmune  thyroid disorder. Furthermore, our 
data pointed to the possibility of using genetic screening Salwa M. Abo El-Khair et al. / American Journal of Biochemistry and Biotechnology 8 (3) (2012) 179-194 
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to identify predisposing factors for autoimmune thyroid 
disorder in patients under interferon therapy.  
5.1. Recommendation 
  Further  large  scale  studies  about  CTLA-4  gene 
+49A/G  and  CT60  polymorphisms  in  chronic  HCV 
patients  under  interferon  therapy  will  help  to  confirm 
results  of  this  preliminary  study  in  our  population. 
Moreover,  an  additional  power  could  be  added  by 
including other polymorphisms to predict thyroid disease 
in  patients  under  interferon  therapy.  Furthermore,  other 
follow  up  works  are  recommended  in  chronic  HCV 
patients after stoppage of interferon therapy.  
  In  addition,  researchers  should  seek  a  better 
understanding  of  the  underlying  pathophysiology  and 
predicting outcome of interferon therapy at its onset and 
identify  HCV  patients  at  risk  of  developing  thyroid 
disorder. Such information should help to improve HCV 
management  and  allow  better  choosing  patients  for 
interferon therapy.  
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